<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978107</url>
  </required_header>
  <id_info>
    <org_study_id>TG4023.01</org_study_id>
    <secondary_id>Eudra CT 2008-005024-90</secondary_id>
    <nct_id>NCT00978107</nct_id>
  </id_info>
  <brief_title>Trial of TG4023 Combined With Flucytosine in Liver Tumors</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous
      intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of
      5-fluorocytosine in patients with primary or secondary hepatic tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-FCU1, flucytosine</intervention_name>
    <description>TG4023: single IT injection; possibility to re-administer once,
Percutaneous IT injections, under radiological or ultrasound imaging guidance
Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),
MTD injected to up to 3 different lesions (Cohort #4)
5-FC (5-fluorocytosine)/flucytosine
Dose and dosing schedule:
Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L
Duration: 2 weeks.
Possible routes of administration:
PO: 500 mg tablets, qid
IV: 1% 250 mL vials, 45-minute infusions.</description>
    <other_name>5-FC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced disease without any other standard of care treatment options:

               -  hepatic metastases of colorectal cancer (CRC) or of other cancers

               -  Hepatocellular carcinoma (HCC)

          -  At least one unresectable target tumor located in the liver, measuring 2-5 cm and
             accessible to IT administration of TG4023 and amenable to radiological measurement
             using RECIST,

          -  Weight ≤ 100 kg,

          -  Patients with stable disease, who have to discontinue chemotherapy because of
             intolerance,

          -  ECOG performance status ≤ 2,

          -  Life expectancy ≥ 3 months,

          -  Hematology:

               -  Absolute neutrophil count &gt; 1,500/mm3,

               -  Hemoglobin &gt; 9g/dL,

               -  Platelet count &gt; 100,000/mm3,

               -  Prothrombin time international normalized ratio (INR) ≤ 2; partial thromboplastin
                  time ≤ 1.66 times upper limit of normal (ULN),

          -  Biochemistry:

               -  Total bilirubin ≤ 3 x ULN,

               -  Aspartate amino-transferase (AST), alanine amino-transferase (ALT), alkaline
                  phosphatase

                    -  5.0 x ULN,

               -  Creatinin clearance ≥ 40 mL/min,

               -  Total albumin ≥ 30 g/L,

          -  Anti-vitamin K anticoagulants should have been switched for low-molecular weight
             heparin prior to TG4023 injection,

          -  Signed, written Independent Ethics Committee (IEC)-approved informed consent.

        Exclusion Criteria:

          -  Child-Pugh stage C hepatic insufficiency,

          -  Impaired renal function (creatinin clearance &lt; 40 mL/min),

          -  Known deficiency in dihydropyrimidine dehydrogenase (DPD) or total DPD deficiency
             diagnosed at baseline in those patients not previously treated with 5-FU-related
             compounds,

          -  Ascites,

          -  Brain metastases,

          -  Significant impairment of gastro-intestinal (GI) tract absorption capacity, such as
             total gastrectomy, gastric mucosal atrophy, extensive intestinal resections or
             malabsorption disease will not be treated by oral 5-FC,

          -  History of bleeding disorders,

          -  Pregnant or breast-feeding women,

          -  Human Immunodeficiency Virus (HIV) positive,

          -  Chronic use of immunodepressants within 4 weeks prior to TG4023 injection or
             immune-depressed patients,

          -  Hypersensitivity to 5-FC,

          -  Hypersensitivity to egg proteins,

          -  Concomitant or previous chemotherapy or targeted therapy within 4 weeks prior to
             TG4023 injection and last treatment with bevacizumab (Avastin®) within 2 months prior
             to TG4023 injection,

          -  Concomitant treatment with anti-inflammatory drugs: systemic cortico-steroids and
             non-steroidal anti-inflammatory drugs (NSAIDs),

          -  Prior gene therapy,

          -  Prior participation in any other research protocol involving an IMP within 2 months
             prior to TG4023 injection,

          -  Major surgery within 6 weeks of TG4023 injection,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette,</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Lyon,</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M, Balloul JM. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther. 2008 Jan;15(1):18-28. Epub 2007 Nov 9.</citation>
    <PMID>17992203</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic tumors</keyword>
  <keyword>Metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

